18-Jun-2026
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
Globe Newswire (Fri, 22-May 8:00 AM ET)
Globe Newswire (Wed, 6-May 7:00 AM ET)
Globe Newswire (Tue, 14-Apr 7:30 AM ET)
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Globe Newswire (Tue, 7-Apr 7:30 AM ET)
Anavex Life Sciences Provides Comprehensive Regulatory Update
Globe Newswire (Mon, 30-Mar 7:30 AM ET)
PRNewswire (Thu, 26-Mar 10:02 PM ET)
Globe Newswire (Wed, 25-Mar 7:30 AM ET)
Globe Newswire (Mon, 23-Mar 7:30 AM ET)
Globe Newswire (Fri, 20-Mar 7:30 AM ET)
AVXL Faces Investor Scrutiny as Shareholder Rights Law Firm Launches Fraud Investigation
Market Chameleon (Thu, 4-Dec 6:22 AM ET)
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Anavex Life Sciences Corp. trades on the NASDAQ stock market under the symbol AVXL.
As of June 18, 2026, AVXL stock price climbed to $2.73 with 5,577,725 million shares trading.
AVXL has a beta of 3.20, meaning it tends to be more sensitive to market movements. AVXL has a correlation of 0.15 to the broad based SPY ETF.
AVXL has a market cap of $252.99 million. This is considered a Small Cap stock.
In the last 3 years, AVXL traded as high as $14.44 and as low as $2.41.
The top ETF exchange traded funds that AVXL belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
AVXL has underperformed the market in the last year with a return of -69.4%, while the SPY ETF gained +26.2%. In the last 3 month period, AVXL fell short of the market, returning -40.0%, while SPY returned +11.6%. However, in the most recent 2 weeks AVXL has outperformed the stock market by returning +3.2%, while SPY returned -1.0%.
AVXL support price is $2.56 and resistance is $2.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVXL shares will trade within this expected range on the day.